

Sequential Alternatives to the Two-Trials Rule

Leonhard Held



**University of
Zurich**^{UZH}

Workshop on Adaptive Designs and Multiple Testing Procedures

Basel, April 20, 2023

The Two-Trials Rule

- FDA requires

“at least two adequate and well-controlled studies, each convincing on its own, to establish effectiveness.”

The Two-Trials Rule

- FDA requires

“at least two adequate and well-controlled studies, each convincing on its own, to establish effectiveness.”

- Usually implemented requiring **one-sided** $p \leq \alpha = 0.025$ in two independent studies.

The Two-Trials Rule

- FDA requires

“at least two adequate and well-controlled studies, each convincing on its own, to establish effectiveness.”

- Usually implemented requiring **one-sided** $p \leq \alpha = 0.025$ in two independent studies.
- Overall T1E rate is $\alpha_{\text{overall}} = \alpha^2 = 0.025^2 = 0.000625$.

The Two-Trials Rule

- FDA requires

“at least two adequate and well-controlled studies, each convincing on its own, to establish effectiveness.”

- Usually implemented requiring **one-sided** $p \leq \alpha = 0.025$ in two independent studies.
- Overall T1E rate is $\alpha_{\text{overall}} = \alpha^2 = 0.025^2 = 0.000625$.
- Nice review in Kennedy-Shaffer (2017)

More Than Two Trials

Therapeutic Innovation & Regulatory Science

<https://doi.org/10.1007/s43441-022-00471-4>

ORIGINAL RESEARCH

A Generalization of the Two Trials Paradigm

Gerd K. Rosenkranz¹ 

More Than Two Trials

Therapeutic Innovation & Regulatory Science

<https://doi.org/10.1007/s43441-022-00471-4>

ORIGINAL RESEARCH

A Generalization of the Two Trials Paradigm

Gerd K. Rosenkranz¹ 

- Requiring **at least 2 out of $n > 2$ trials** to be significant at 0.025 is too lax.

More Than Two Trials

Therapeutic Innovation & Regulatory Science

<https://doi.org/10.1007/s43441-022-00471-4>

ORIGINAL RESEARCH

A Generalization of the Two Trials Paradigm

Gerd K. Rosenkranz¹ 

- Requiring **at least 2 out of $n > 2$ trials** to be significant at 0.025 is too lax.
- Requiring **all n trials** to be significant at 0.025 is too stringent.

More Than Two Trials

Therapeutic Innovation & Regulatory Science

<https://doi.org/10.1007/s43441-022-00471-4>

ORIGINAL RESEARCH

A Generalization of the Two Trials Paradigm

Gerd K. Rosenkranz¹ 

- Requiring **at least 2 out of $n > 2$ trials** to be significant at 0.025 is too lax.
- Requiring **all n trials** to be significant at 0.025 is too stringent.
- Rosenkranz (2023) addresses the problem by requiring that

“the type-I error rate of any procedure involving more than two trials shall equal the type-I error rate from the two trials rule.”

More Than Two Trials

Therapeutic Innovation & Regulatory Science
<https://doi.org/10.1007/s43441-022-00471-4>

ORIGINAL RESEARCH

A Generalization of the Two Trials Paradigm

Gerd K. Rosenkranz¹ 

- Requiring **at least 2 out of $n > 2$ trials** to be significant at 0.025 is too lax.
 - Requiring **all n trials** to be significant at 0.025 is too stringent.
 - Rosenkranz (2023) addresses the problem by requiring that
“the type-I error rate of any procedure involving more than two trials shall equal the type-I error rate from the two trials rule.”
- **“2-of-3 rule”** with adjusted significance level $\alpha_* = 0.0145$

The Harmonic Mean χ^2 Test



Appl. Statist. (2020)

The harmonic mean χ^2 -test to substantiate scientific findings

Leonhard Held

University of Zurich, Switzerland

The Harmonic Mean χ^2 Test



Appl. Statist. (2020)

The harmonic mean χ^2 -test to substantiate scientific findings

Leonhard Held
University of Zurich, Switzerland

- Compute the **harmonic mean Z_H^2** of squared Z -values Z_1^2, \dots, Z_n^2 to obtain

$$\chi_n^2 = n \cdot Z_H^2 = \frac{n^2}{\sum_{i=1}^n 1/Z_i^2} \stackrel{H_0}{\sim} \chi^2(1 \text{ df})$$

The Harmonic Mean χ^2 Test



Appl. Statist. (2020)

The harmonic mean χ^2 -test to substantiate scientific findings

Leonhard Held
University of Zurich, Switzerland

- Compute the **harmonic mean Z_H^2** of squared Z -values Z_1^2, \dots, Z_n^2 to obtain

$$\chi_n^2 = n \cdot Z_H^2 = \frac{n^2}{\sum_{i=1}^n 1/Z_i^2} \stackrel{H_0}{\sim} \chi^2(1 \text{ df})$$

- Exact overall T1E control at level α_{overall} is obtained with critical value c_n .

Necessary Success Bounds on p -Values

$$\text{The success criterion } X_n^2 \geq c_n \iff T_n = \sum_{i=1}^n 1/Z_i^2 \leq d_n = \frac{n^2}{c_n}$$

requires $1/Z_i^2 \leq d_n$, which implies **necessary** success bounds on all p -values:

	bound on p -value		
α_{overall}	$n = 2$	$n = 3$	$n = 4$
0.025^2	0.065	0.17	0.26

Formalizes the meaning of

*“at least two adequate and well-controlled studies,
each convincing on its own, to establish effectiveness”*

No such bounds exist for Fisher, Stouffer, 2-of-3 rule

Project Power for 2 Trials

- Of central interest is the overall **project power**.
- Can be easily calculated through Monte Carlo simulation:

Trial power	Project power (%)	
	two-trials rule	harmonic
80	64	71
90	81	87



Sequential Conduct of 3 Trials

- 2-of-3 rule
 - Cannot stop after trial 1


Sequential Conduct of 3 Trials

- **2-of-3 rule**
 - Cannot stop after trial 1
 - Trial 1 and 2 could be run in parallel

Sequential Conduct of 3 Trials

- **2-of-3 rule**
 - Cannot stop after trial 1
 - Trial 1 and 2 could be run in parallel
 - Can stop after trial 2 for both **failure** and **success**


Decisions after trial 1 and 2:



Sequential Conduct of 3 Trials

- **2-of-3 rule**
 - Cannot stop after trial 1
 - Trial 1 and 2 could be run in parallel
 - Can stop after trial 2 for both **failure** and **success**
 - **Failure** if $p_1, p_2 = 0.02$ (!)


Decisions after trial 1 and 2:



Sequential Conduct of 3 Trials

- **2-of-3 rule**
 - Cannot stop after trial 1
 - Trial 1 and 2 could be run in parallel
 - Can stop after trial 2 for both **failure** and **success**
 - **Failure** if $p_1, p_2 = 0.02$ (!)
- **Harmonic mean test**
 - Can stop after trial 1 for **failure** (if $p_1 > 0.17$)


Decisions after trial 1 and 2:



Sequential Conduct of 3 Trials

- **2-of-3 rule**
 - Cannot stop after trial 1
 - > Trial 1 and 2 could be run in parallel
 - Can stop after trial 2 for both **failure** and **success**
 - **Failure** if $p_1, p_2 = 0.02$ (!)
- **Harmonic mean test**
 - Can stop after trial 1 for **failure** (if $p_1 > 0.17$)
 - Can stop after trial 2 for **failure**


Decisions after trial 1 and 2:



Sequential Conduct of 3 Trials


- **2-of-3 rule**
 - Cannot stop after trial 1
 - > Trial 1 and 2 could be run in parallel
 - Can stop after trial 2 for both **failure** and **success**
 - **Failure** if $p_1, p_2 = 0.02$ (!)
- **Harmonic mean test**
 - Can stop after trial 1 for **failure** (if $p_1 > 0.17$)
 - Can stop after trial 2 for **failure**
 - **Success** is only possible with 3 trials

Decisions after trial 1 and 2:




Sequential Conduct of 3 Trials

2-of-3 rule




Sequential Conduct of 3 Trials

2-of-3 rule




Harmonic mean




Project Power and Expected Number of Trials

Project power



Expected number of trials



The Sequential Harmonic Mean Test

- Test for success after 2nd and 3rd trial at level α_{adjusted} .
- Exact T1E control at level α_{overall} requires **multiplicity adjustments** based on


$$T_3 = \underbrace{1/Z_1^2 + 1/Z_2^2}_{=T_2 \sim \text{IG}(1/2,2)} + \underbrace{1/Z_3^2}_{\sim \text{IG}(1/2,1/2)}$$

- Can be extended to test also after 1st trial.
- Adjusted level and thresholds d_i for $\alpha_{\text{overall}} = 0.025^2$:

	α_{adjusted}	threshold		
		d_1	d_2	d_3
hMean	0.025^2			1.14
2 3 seq hMean	0.018^2		0.39	1.00
1 2 3 seq hMean	0.015^2	0.081	0.36	0.92


The Sequential Harmonic Mean Test

2|3 version




The Sequential Harmonic Mean Test

2|3 version




1|2|3 version




Possible Decisions after Trial 1

Trials 2 and 3 can sometimes be conducted in parallel:




Possible Decisions after Trial 2




Project Power and Expected Number of Trials

Project power



Expected number of trials



Summary

The harmonic mean χ^2 test

- requires each trial to be convincing on its own

Summary

The harmonic mean χ^2 test

- requires each trial to be convincing on its own
- allows for stopping after the 1st trial

Summary

The harmonic mean χ^2 test

- requires each trial to be convincing on its own
- allows for stopping after the 1st trial
- leads to more appropriate inferences than the 2-of-3 rule

Summary

The harmonic mean χ^2 test

- requires each trial to be convincing on its own
- allows for stopping after the 1st trial
- leads to more appropriate inferences than the 2-of-3 rule
- can be applied sequentially to stop for success after the 2nd or 1st trial

Summary

The harmonic mean χ^2 test

- requires each trial to be convincing on its own
- allows for stopping after the 1st trial
- leads to more appropriate inferences than the 2-of-3 rule
- can be applied sequentially to stop for success after the 2nd or 1st trial
- has increased project power and requires less trials

References

- Held, L. (2020). The harmonic mean χ^2 -test to substantiate scientific findings. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, 69(3):697–708.
- Kennedy-Shaffer, L. (2017). When the alpha is the omega: *P*-values, “substantial evidence,” and the 0.05 standard at FDA. *Food and Drug Law Journal*, 72(4):595–635.
- Rosenkranz, G. K. (2023). A generalization of the two trials paradigm. *Therapeutic Innovation & Regulatory Science*, 57:316–320.